PSFL2915
Based on 1 Customer Validation
PSFL2915 is a selective, orally active P2X receptor inhibitor with oral effectiveness, with an IC50 of 0.319 μM for human P2X3, 0.261 μM for rat P2X2/3, and 13.3 μM for human P2X2. PSFL2915 exhibits ~42-fold selectivity over human P2X2. PSFL2915 can be used for the research of chronic cough.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.72%
- CAS No.: 88134-39-8
- 화학식: C15H10O13S2
- 분자량:462.36
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
All P2X Receptor Isoforms
More
Biological Activity
PSFL2915 (0.01-3 μM; 0.6 μM; 1 μM) is a noncompetitive, Mg2+-dependent allosteric inhibitor of hP2X3, with ~42-fold selectivity for hP2X3 over hP2X2, potent inhibition of rP2X2/3 heterotrimers, and low activity at other P2X subtypes[1].
PSFL2915 (1 μM) exerts inhibitory effects by targeting the inner pocket of the head domain of hP2X3, as evidenced by potent inhibition of the hP2X4 chimera containing this hP2X3 domain[1].
PSFL2915 (500 nM) prevents the ATP-induced conformational change of the inner pocket of the head domain in hP2X3, which is required for channel activation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
PSFL2915 (10 mg/kg; i.g.; twice daily; 7 days) produces significant cough-suppressant activity in male Hartley guinea pigs with citric acid/ATP-induced chronic cough, with potency equivalent to Gefapixant (HY-101588) at the same dose[1].
PSFL2915 (15 mg/kg; i.g.; twice daily; 7-10 days) does not impair taste perception in mice, as measured by two-bottle preference tests for bitter and sweet tastants[1].
PSFL2915 (10-20 mg/kg; i.p.) does not impair bitter taste perception in rats, as measured by two-bottle preference testing with quinine[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (male, 6-7 weeks old)[1]
-
Dosage:15 mg/kg
-
Administration:i.g.; twice daily; 7 days
-
Result:Significantly reduced cough frequency, with efficacy comparable to Gefapixant (HY-101588) at an equivalent dose.
-
Animal Model:C57BL/6 mice (male, 6-7 weeks old)[1]
-
Dosage:15 mg/kg
-
Administration:i.g.; twice daily; 7-10 days
-
Result:Did not alter quinine consumption rate 46.1%.
Did not alter acesulfame-K consumption rate 86.7%.
Chemical Information
-
CAS No. 88134-39-8
-
Appearance Solid
-
분자량 462.36
-
화학식 C15H10O13S2
-
Color Off-white to light yellow
-
SMILES
O=C1C(O)=C(C2=CC(S(=O)(O)=O)=C(O)C(O)=C2)OC3=C(S(=O)(O)=O)C(O)=CC(O)=C31
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
용액&용해도
DMSO : 10 mg/mL (21.63 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (2.16 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1 mg/mL (2.16 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1628 mL | 10.8141 mL | 21.6282 mL | 54.0704 mL |
| 5 mM | 0.4326 mL | 2.1628 mL | 4.3256 mL | 10.8141 mL | |
| 10 mM | 0.2163 mL | 1.0814 mL | 2.1628 mL | 5.4070 mL | |
| 15 mM | 0.1442 mL | 0.7209 mL | 1.4419 mL | 3.6047 mL | |
| 20 mM | 0.1081 mL | 0.5407 mL | 1.0814 mL | 2.7035 mL |
PSFL2915 Related Classifications
HY-186112 Related Classifications
Powered by Bioz